International Journal of Pharmacology and Clinical Research

ISSN Print: 2664-7613
ISSN Online: 2664-7621
Impact Factor: RJIF 8.29
IJPCR 2025; 7(2): 571-573
www.pharmacologyjournal.in
Received: 18-10-2025
Accepted: 22-11-2025

JS Venkatesh
Professor, Department of Pharmacy Practice, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Dr. Manasa T
Professor, Department of Pharmacy Practice, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Sneha Charmika
Professor, Department of Pharmacy Practice, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Preetham GB
Professor, Department of Pharmacy Practice, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Sheba John
Pharm D Intern, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Corresponding Author:
JS Venkatesh
Professor, Department of Pharmacy Practice, SCS College of Pharmacy, Harapanahalli, Karnataka, India

Efficacy and safety of anticoagulants in venous thromboembolism

JS Venkatesh, Manasa T, Sneha Charmika, Preetham GB and Sheba John

DOI: https://www.doi.org/10.33545/26647613.2025.v7.i2g.154

Abstract
Venous Thromboembolism (VTE), which includes deep vein thrombosis and pulmonary embolism, remains a significant global health burden due to its high rates of illness and death. The primary approach to both treating and preventing VTE is anticoagulation. This review summarizes current research on the effectiveness and safety of major anticoagulant classes such as heparins, vitamin K antagonists, and direct oral anticoagulants. It highlights their mechanisms, key clinical evidence, and recent developments in VTE care, emphasizing the need to balance the benefits of preventing clot formation with the risk of bleeding complications.

Keywords: Vitamin K Antagonist, anticoagulants, venous thromboembolism, heparin

Introduction
Venous Thromboembolism (VTE) develops when a clot forms within a vein, most often presenting as Deep Vein Thrombosis (DVT) in the legs or as a pulmonary embolism (PE). In most cases, a PE results from a clot that breaks off from a lower-limb DVT and migrates to the pulmonary arteries. Less commonly, clots may originate in the right atrium of the heart or form directly within the lung's blood vessels as pulmonary thrombosis. Venous clots may also arise in other locations, including the veins of the upper limbs, the splanchnic circulation, and the cerebral venous sinuses. The primary goal of VTE treatment is to prevent thrombus extension and embolization, reduce the risk of recurrence, and minimize long-term complications like post-thrombotic syndrome.
Anticoagulants achieve this by inhibiting the coagulation cascade, thereby preventing the formation and growth of new clots.

Anticoagulant Classes for VTE
The management of Venous Thromboembolism (VTE) has improved greatly with the availability of newer anticoagulant drugs. These medications fall into two main categories.

Parenteral anticoagulants include
- **Unfractionated Heparin (UFH):** A combination of glycosaminoglycans that increases the activity of antithrombin, leading to the inhibition of thrombin and Factor Xa. It is given through an intravenous infusion and requires regular aPTT monitoring.
- Low-Molecular-Weight Heparins (LMWHs) such as enoxaparin and dalteparin. These are smaller fragments of UFH with a more predictable effect, mainly targeting Factor Xa. They are administered by subcutaneous injection and usually do not need routine laboratory testing, making outpatient use easier.
- **Fondaparinux:** A synthetic pentasaccharide factor Xa inhibitor that also binds antithrombin but instead accelerates its inhibition of thrombin. UFH, LMWH, and fondaparinux are given only by injection. Protamine sulfate can counteract the effects of UFH and LMWH by binding to them and blocking their anticoagulant action.

Oral anticoagulants include
Vitamin K Antagonists (VKAs), including warfarin, acenocoumarol, and phenprocoumon, work by blocking the vitamin K cycle, specifically by inhibiting the enzyme VKORC1.

This prevents the regeneration of reduced vitamin K (KH_2), which is required for the carboxylation and activation of clotting factors II, VII, IX, X, and proteins C and S. Because factors X and II have long half-lives, full anticoagulation with warfarin takes several days, and bridging with a parenteral anticoagulant is needed initially due to the early reduction of proteins C and S. These drugs require careful dose adjustment and regular INR monitoring to ensure safe and effective treatment. Direct Oral Anticoagulants (DOACs/NOACs) such as rivaroxaban, apixaban, edoxaban (Factor Xa inhibitors), and dabigatran (a direct thrombin inhibitor). They provide predictable anticoagulation with fixed doses and do not require routine monitoring, making VTE therapy more convenient for patients.

Efficacy and Safety: Comparative Overview

- **Efficacy:** Clinical Trials have consistently demonstrated the high efficacy of anticoagulants in preventing VTE recurrence.
- **Acute Phase (Initial Treatment):** LMWHs, UFH, and fondaparinux have long been the standard for the initial management of VTE. DOACs especially rivaroxaban and apixaban have proven to be just as effective as the older treatment strategy that uses an injectable anticoagulant followed by a VKA. Some DOACs, such as rivaroxaban and apixaban, can be started immediately as the only medication, whereas others like dabigatran and edoxaban must first be preceded by a course of injectable therapy.
- **Long-term and Extended Therapy:** Patients with unprovoked VTE or ongoing risk factors often require long-term or lifelong anticoagulation. Studies have shown that both VKAs and DOACs help lower the chances of VTE coming back over extended periods. A network meta-analysis revealed that all oral anticoagulants reduce recurrence compared with placebo. While VKAs may offer the greatest decrease in recurrence, this advantage is often limited by their higher risk of bleeding.
- **Safety:** The primary safety concern with all anticoagulants is the risk of bleeding. The challenge in VTE management is to achieve a balance between efficacy and safety, optimizing clot prevention while minimizing the risk of major hemorrhage.

Bleeding Risk

- **VKAs:** Warfarin is associated with a greater risk of major bleeding compared to DOACs. The need for strict dietary management, drug interactions, and frequent INR monitoring also contributes to a higher rate of bleeding events and complicates patient management.
- **DOACs:** Many studies have shown that DOACs cause fewer major and intracranial bleeding events compared to VKAs. This better safety profile is a major factor behind their increased use. Still, bleeding remains a significant concern, and patients taking DOACs must be monitored and must follow their treatment plan closely.

Special Considerations and Evolving Management

VTE in Specific Patient Populations

- **Cancer-Associated VTE (CAT):** VTE is a leading cause of death in patients with cancer. For decades, LMWHs were the gold standard for CAT due to superior efficacy compared to VKAs. However, recent guidelines have increasingly supported the use of DOACs, particularly apixaban and rivaroxaban, which have demonstrated non-inferiority to LMWHs with a similar or even reduced bleeding risk, especially for gastrointestinal and genitourinary cancers.
- **Morbid Obesity:** Patients with a body mass index (BMI) over 40 kg or weight greater than 120 kg were largely excluded from pivotal DOAC trials. This has led to concerns about the efficacy of standard fixed-dose DOACs in this population due to a larger volume of distribution. While some guidelines have been cautious, real-world data and sub-analyses of clinical trials suggest that standard doses of rivaroxaban and apixaban are effective and safe in most patients with morbid obesity, though monitoring of drug levels may be considered in extreme cases.

Risk Stratification and Duration of therapy

Determining how long a patient should remain on anticoagulation after the first 3-6 months is essential, especially for those with unprovoked VTE. The choice to discontinue or prolong treatment must carefully weigh the likelihood of another clot against the possibility of bleeding complications.

Provoked vs Unprovoked VTE

When VTE occurs due to a temporary trigger such as surgery or injury, a 3-month treatment course is usually adequate. In contrast, unprovoked VTE carries a much higher chance of recurrence about 10% each year so many patients may need long-term or even lifelong anticoagulation.

Risk Scores and D-dimer Testing

Several tools help guide decisions on extending therapy. A high D-dimer level measured one month after stopping anticoagulation strongly predicts recurrence and is increasingly used to determine whether treatment should continue. Additional factors such as being male, having obesity, or showing persistent clot on ultrasound also raise recurrence risk and may support ongoing anticoagulation.

Reversal Agents and Bleeding Management

One major safety benefit of DOACs is the availability of targeted reversal medications:-

- **Idarucizumab:** This antidote is designed to neutralize dabigatran quickly and completely. It is extremely valuable when a patient experiences severe bleeding or requires urgent surgery.
- **Andexanet Alfa:** This reversal agent is a modified recombinant factor Xa molecule that acts as decoy to bind and sequester direct factor Xa inhibitors such as apixaban and rivaroxaban. Clinical trials have shown encouraging outcomes, making it an important option for managing bleeding emergencies.

Future Directions and Emerging Insights

The field of VTE management is not static, and ongoing research points to several key future trends:-

- **Novel Anticoagulants (Factor XI/XIa Inhibitors):** The most promising new class of anticoagulants in development are inhibitors of Factor XI and Factor XIa.

These agents are based on the hypothesis that Factor XI is crucial for pathological thrombus formation but plays a minor role in hemostasis (the body's normal response to stop bleeding). Early-phase clinical trials have shown these drugs to be as effective as current anticoagulants in preventing VTE but with a significantly lower bleeding risk. This could represent a paradigm shift, offering a new level of safety for patients requiring long-term anticoagulation.

- **Personalized Treatment Approaches:** VTE therapy is expected to become more personalized in the future. This may include using genetic information, biomarkers such as D-dimer, and individual risk factors to choose the safest and most effective anticoagulant. Modern tools like artificial intelligence and machine learning are also being used to develop prediction models for bleeding and clot recurrence, improving treatment decisions.
- **Long-term VTE after COVID-19:** COVID-19 emphasized the major role of clotting problems, not only during the infection but also in the long-term condition called "long COVID". Researchers are studying why some patients remain at higher risk of clotting and whether extended or preventive anticoagulation could help. This has created a new area of focus in VTE care.

Conclusion

Anticoagulant medications play a crucial role in treating and preventing venous thromboembolism. The introduction of DOACs has greatly improved VTE management by offering strong effectiveness with a lower risk of major bleeding compared to older drugs like warfarin. Their predictable dosing and lack of routine monitoring make them easier and safer for patients to use. Although DOACs are now the recommended first-line option for most individuals with VTE, it is still important for healthcare providers to understand the benefits and limitations of every available anticoagulant to ensure the most suitable, patient-focused choices are made. Tools such as D-dimer testing and clinical risk assessment models, along with the availability of specific reversal agents, have enhanced safety and helped guide personalized treatment plans. The future of VTE management appears to be heading towards even safer and more tailored therapies, with novel drug classes like Factor XI inhibitors poised to further improve the balance between efficacy and safety.

Reference

1. New anticoagulants for the prevention and treatment of venous thromboembolism. Biomol Ther. 2017;25(5):461-470.
2. A review of the efficacy and safety profiles of the novel oral anticoagulants in the treatment and prevention of venous thromboembolism. [Journal name missing]. 2018;40(12):2140-2167.
3. Direct oral anticoagulants for the treatment of acute venous thromboembolism. Am J Med. 2018;131(4):427-434.
4. Efficacy and safety of dabigatran compared with warfarin for the treatment of acute venous thromboembolism: A systematic review and meta-analysis. Lancet Haematol. 2015;2(8):e336-e344.
5. Apixaban versus enoxaparin for the prevention of venous thromboembolism after hip or knee replacement: A randomized controlled trial. N Engl J Med. 2010;363(26):2487-2498.
6. Rivaroxaban for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
7. Anticoagulation drug therapy: A review. [Journal name missing]. 2015 Jan;16(1):1.
8. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(24):1406-1415.
9. Long-term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis. J Thromb Haemost. 2021;19(11):2801-281.
10. Sandblad KG. Venous thromboembolism: Risk factors, comorbidities, and treatment-associated risk of bleeding; 2023.
11. Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. 2015;35(3):513-519.
12. The effectiveness of new oral anticoagulants in the treatment of lower extremity venous thrombosis: A clinical study. Konuralp Med J. 2021;13(2):312-318.